➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Express Scripts
Dow
McKesson
McKinsey

Last Updated: October 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,888,342

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,888,342 protect, and when does it expire?

Patent 7,888,342 protects SAVELLA and is included in one NDA.

This patent has sixteen patent family members in nine countries.

Summary for Patent: 7,888,342
Title:Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
Abstract:The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
Inventor(s): Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (Encinitas, CA)
Assignee: Cypress Bioscience, Inc. (San Diego, CA)
Application Number:12/644,510
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,888,342
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,888,342

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 RX Yes No   Start Trial   Start Trial MANAGEMENT OF FIBROMYALGIA (FM)   Start Trial
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 RX Yes No   Start Trial   Start Trial MANAGEMENT OF FIBROMYALGIA (FM)   Start Trial
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-003 Jan 14, 2009 RX Yes Yes   Start Trial   Start Trial MANAGEMENT OF FIBROMYALGIA (FM)   Start Trial
Allergan SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 RX Yes No   Start Trial   Start Trial MANAGEMENT OF FIBROMYALGIA (FM)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Moodys
Express Scripts
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.